Improved post-transcriptional processing of an MDR1 retrovirus elevates expression of multidrug resistance in primary human hematopoietic cells

Gene Therapy
R KnipperC Baum

Abstract

We describe the functional analysis of a novel retroviral vector, SF91m3, which was designed for improved expression of the in vivo selectable marker, multidrug resistance 1 gene (MDR1), in hematopoietic cells. SF91m3 combines several promising features. The vector backbone lacks viral coding sequences and AUG-start codons 5' of the MDR1 cDNA. A point mutation of a cryptic splice acceptor of the MDR1 cDNA increases the probability of transferring an intact provirus. The titer of a PG13 packaging cell clone containing a single proviral integration is high (>2 x 10(6) particles/ml from frozen stocks of serum-free vector harvests). Human hematopoietic cells transduced with SF91m3 reliably express MDR1 before and after passage through NOD/SCID mice, as shown by quantitative PCR and efflux assays with rhodamine 123 or Hoechst 33342. Finally, SF91m3 mediates resistance to escalated doses of cytotoxic agents, as shown by survival and differentiation of transduced colony-forming cells in the presence of colchicine at 48 ng/ml (>10 x IC(50)). Thus, SF91m3 may represent an interesting candidate for future trials addressing the safety and utility of MDR1 gene transfer; moreover, this study demonstrates that sequence alterations improving ...Continue Reading

References

Oct 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·S PoddaA Bank
Dec 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·M GrezW Ostertag
Apr 12, 1994·Proceedings of the National Academy of Sciences of the United States of America·J M AranI Pastan
Jan 24, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C HesdorfferK Antman

❮ Previous
Next ❯

Citations

Sep 6, 2003·Archives of Medical Research·Kevin R Smith
May 6, 2003·Drug Resistance Updates : Reviews and Commentaries in Antimicrobial and Anticancer Chemotherapy·S LaufsS Fruehauf
Aug 22, 2002·Nature Reviews. Cancer·Brian P Sorrentino
Jul 23, 2005·Cancer Gene Therapy·Tulin Budak-AlpdoganJoseph R Bertino
Dec 4, 2003·Expert Opinion on Biological Therapy·S FruehaufS Laufs
Mar 29, 2002·International Journal of Cancer. Journal International Du Cancer·Alexander CarpinteiroSusanna Hegewisch-Becker
Jul 28, 2009·Blood Cells, Molecules & Diseases·Rafael MorenoJosep M Aran
Jul 2, 2010·Leukemia Research·Anne Van den BroekePhilip Griebel
Sep 28, 2002·Molecular Therapy : the Journal of the American Society of Gene Therapy·Marlon R VeldwijkStefan Fruehauf
Oct 29, 2004·Molecular Therapy : the Journal of the American Society of Gene Therapy·Michael D MilsomLeslie J Fairbairn

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antimicrobial Resistance (ASM)

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Antimicrobial Resistance

Antimicrobial resistance poses a significant threat to the continued successful use of antimicrobial agents for the treatment of bacterial infections.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.